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Purpose
The aim of this study was to evaluate the ability of sequential 18F-fluorodeoxyglucose posi-
tron emission tomography/computed tomography (18F-FDG-PET/CT) after one cycle of neo-
adjuvant chemotherapy (NAC) to predict chemotherapy response before interval debulking 
surgery (IDS) in advanced-stage ovarian cancer patients. 
Materials and Methods
Forty consecutive patients underwent 18F-FDG-PET/CT at baseline and after one cycle of 
NAC. Metabolic responses were assessed by quantitative decrease in the maximum stand-
ardized uptake value (SUVmax) with PET/CT. Decreases in SUVmax were compared with can-
cer antigen 125 (CA-125) level before IDS, response rate by Response Evaluation Criteria 
in Solid Tumors criteria before IDS, residual tumor at IDS, and I chemotherapy response 
score (CRS) at IDS.    
Results
A 40% cut-off for the decrease in SUVmax provided the best performance to predict CRS 
3 (compete or near-complete pathologic response), with sensitivity, specificity, and accu-
racy of 81.8%, 72.4%, and 72.4%, respectively. According to this 40% cut-off, there were 
17 (42.5%) metabolic responders (≥ 40%) and 23 (57.5%) metabolic non-responders 
(< 40%). Metabolic responders had higher rate of CRS 3 (52.9% vs. 8.7%, p=0.003), CA-
125 normalization (< 35 U/mL) before IDS (76.5% vs. 39.1%, p=0.019), and no residual 
tumor at IDS (70.6% vs. 31.8%, p=0.025) compared with metabolic non-responders. There 
were significant associations with progression-free survival (p=0.021) between metabolic 
responders and non-responders, but not overall survival (p=0.335). 
Conclusion
Early assessment with 18F-FDG-PET/CT after one cycle of NAC can be useful to predic 
response to chemotherapy before IDS in patients with advanced-stage ovarian cancer.
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Introduction
Neoadjuvant chemotherapy (NAC) followed by interval 
debulking surgery (IDS) can be an alternative to primary 
debulking surgery for treating advanced-stage ovarian cancer 
when optimal cytoreduction cannot be achieved [1,2]. Chem-
otherapy sensitivity has been a well-known prognostic factor 
for survival, and evaluation of NAC response is mostly based 
on computed tomography (CT) imaging after three to four 
cycles of NAC. Earlier evaluation of NAC response would 
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allow for avoidance of unnecessary surgical complications 
and toxicity due to ineffective treatment.
Recently, several studies have shown that 18F-fluorodeo-
xyglucose positron emission tomography/computed tomog-
raphy (18F-FDG-PET/CT) may be useful for predicting early 
response to NAC in other malignancies [3-9]. However, there 
are only a few studies on the use of PET/CT for evaluation 
of response to NAC in ovarian cancer [10-13]. Avril et al. [10] 
showed that the sequential 18F-FDG-PET/CT after one cycle 
of NAC predicted patient’s outcome. Other than the result of 
this study [10], there is no data on the use of PET/CT after one 
cycle of NAC to predict chemotherapy response before IDS.
Histopathological changes seen at IDS reflect direct NAC 
response [14-17]. However, there is no consensus regarding 
the prognostic value of the pathologic grading system to 
assess NAC response at IDS. Recently, Böhm et al. proposed 
the 3-tier chemotherapy response score (CRS) system for 
ovarian cancer, and our group performed an external vali-
dation of this system confirming a high reproducibility and 
prognostic value [18,19]. As pathologic response could be a 
surrogate endpoint, we evaluated how the early tumor meta-
bolic change during NAC correlated with histopathological 
response observed at IDS. The aim of this study was to inves-
tigate the ability of PET parameters after one cycle of chemo-





From 2016 to 2018, 40 consecutive patients diagnosed with 
International Federation of Gynecology and Obstetrics stage 
IIIC or IV high-grade serous ovarian cancer underwent base-
line 18F-FDG-PET/CT before starting NAC. Thirty-eight of 40 
patients underwent diagnostic laparoscopy showing Fagotti 
score ≥ 8 [20] before NAC, while two patients received NAC 
after histologically confirmed by cytologic evaluation of 
ascites without diagnostic laparoscopy. All of them under-
went a second 18F-FDG-PET/CT examination after one cycle 
of NAC. After the completion of NAC, 39 patients under-
went IDS (Fig. 1). One patient did not receive IDS because 
she refused surgery and follow-up loss after four cycles of 
NAC.  
2. Protocol-based treatment
Diagnostic work-up included contrast-enhanced CT scan 
of the chest/pelvis as well as FDG-PET/CT were obtained for 
all patients at baseline to determine the tumor burden.
In our institution, NAC was performed as the primary 
treatment strategy, when one of the following three selection 
criteria was met [21]: (1) pulmonary and/or hepatic paren-
chymal metastases observed on initial imaging work-up, (2) 
patients with poor performance status and high operative 
risk due to medical comorbidities, or (3) optimal debulking 
surgery (i.e., ≤ 1 cm of residual disease at debulking surgery) 
was unsuitable due to high tumor burden (Fagotti score ≥ 8). 
During diagnostic laparoscopy, the degree of tumor burden 
was described by Fagotti score.
All patients, preferably, are recommended to receive three 
cycles of NAC and IDS, as well as three cycles of postopera-
tive adjuvant chemotherapy (POAC). For NAC and POAC, 
all patients received platinum-based combination chemo-
therapy (paclitaxel [175 mg/m2]+carboplatin [area under the 
curve of 5 to 6]). 
All patients underwent surgery with the intent to achieve 
complete cytoreduction (no gross residual disease) and fol-
lowed the same routine, beginning with complete omentec-
tomy, hysterectomy, bilateral salpingo-oophorectomy, and 
removal of all macroscopically detectable lesions using surgi-
cal resection. Furthermore, 29 patients underwent IDS follow-
ing hyperthermic intraperitoneal chemotherapy.
3. 18F-FDG-PET/CT imaging and imaging analysis
All subjects were requested to fast for over 8 hours before 
PET acquisition. Blood glucose concentrations were confir-
med to be < 140 mg/dL at the time of FDG injection. 
Intravenously, 5.5 MBq of 18F-FDG per kg body weight 
Fig. 1.  Overall flow chart of positron emission tomography/computed tomography (PET/CT), neoadjuvant chemotherapy (NAC), and 
interval debulking surgery (IDS). SUVmax, maximum standardized uptake value; CRS, chemotherapy response score; CA-125, cancer anti-
gen 125. a)Two patients received four cycles of NAC.
NAC #1 NAC #2 NAC #3 NAC #4a)
IDSPET/CTPET/CT
ΔSUVmax CRS, residual disease, response rate, CA-125
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were injected. After 60 minutes, integrated FDG-PET/CT 
was performed using a dedicated PET/CT scanner (Discov-
ery STE, GE Healthcare, Milwaukee, WI). Whole body spi-
ral CT scan was performed from the vertex of the skull to 
the mid-thigh using the following parameters: 120 kVp, 30 
mA, 0.8-second rotation time, 3.75 mm helical thickness, 27 
mm per rotation (speed), 2.5 mm scan reconstruction, with a 
reconstruction index of 1.25 mm, 15.7 cm field of view, and a 
512×512 matrix. PET scan was acquired from the cerebellum 
to the proximal thigh, and acquisition time was 3 minutes 
per bed position using the 3D-mode. Attenuation corrected 
PET data were reconstructed iteratively using an ordered-
subset expectation maximization algorithm. 
4. PET parameter
All 18F-FDG-PET/CT images were reviewed blinded to the 
clinical outcome by two nuclear medicine physicians. Each 
region with a higher FDG uptake than the background was 
considered significant. The maximum standardized uptake 
values (SUVmax) were measured by drawing a circular region 
of interest (ROI) at the site of the maximum 18F-FDG uptake 
on the transaxial PET images. The SUV of the ROI was cal-
culated as follows: (decay-corrected activity [MBq] per tissue 
volume [mL])/(injected 18F-FDG dose [MBq] per body mass 
[g]).
Seven tumor lesions (right upper quadrant, left upper 
quadrant, sub-hepatic area, mesentery, pelvis, right ovary, 
and left ovary) per patients were identified; and SUVmax at 
each examination were calculated. The SUVmax after one cycle 
of NAC was compared with that of the baseline study. Mul-
tiple metastatic tumors observed by 18F-FDG-PET/CT were 
found in all patients. Therefore, we used the lesion with the 
lowest change in 18F-FDG uptake for the study analysis based 
on the rationale that the metastatic tumor with the worst 
response would determine survival. The change in SUVmax 
after one cycle of chemotherapy was expressed as ΔSUVmax 
(%)=100×(1st cycle SUVmax–baseline SUVmax)/baseline SUVmax.
5. Assessment of response to NAC
1) Cancer antigen 125 normalization
Cancer antigen 125 (CA-125) levels were determined 
before diagnostic laparoscopy, before each NAC cycle, and 
before IDS. CA-125 response criterion was a complete nor-
malization of CA-125 levels before IDS (< 35 U/mL). 
 2) Imaging response (CT) by Response Evaluation Crite-
ria in Solid Tumors 
Patients’ radiological responses to NAC were generally 
estimated with contrast-enhanced CT before IDS and classi-
fied according to the Response Evaluation Criteria in Solid 
Tumors (RECIST) as complete response (CR), partial respon-
se (PR), stable disease, and progressive disease [22].
3) Residual tumor after IDS
During IDS, we collected information on the maximal 
diameter of the residual lesion for evaluation of the residual 
disease. Residual disease was reported using the following 
criteria: from no gross (microscopic) residual disease, 0.0-0.5 
cm, 0.5-1.0 cm, 1.0-2.0 cm, or residual disease > 2.0 cm in the 
largest diameter.
4) Histopathological response by CRS
For the assessment of NAC-induced histopathological 
changes, specimens were taken from each of these three sites 
(omentum, right adnexa, and left adnexa) during IDS. All 
available hematoxylin and eosin–stained slides were revie-
wed by an experienced gynecologic pathologist (H.-S.K.). As 
Bohm et al. [18] and Lee et al. [19] reported significant cor-
relations between outcome and omental CRS, we analyzed 
the histo-pathological response to NAC with omental CRS.
Specimens with no or minimal tumor response, appreci-
able tumor response, and complete or near-CR were indicat-
ed as CRS 1, 2, and 3, respectively. Patients with CRS 1 or 2 
were considered as histopathological non-responders, while 
patients with CRS 3 were considered as histopathological 
responders.
6. Statistical analysis
Correlations between CRS and PET parameter were exam-
ined with the Mann-Whitney U test. The predictive perfor-
mance regarding the identification of CRS 3 was evaluated 
using the receiver operating characteristic (ROC) curve ana-
lysis. 
Associations between metabolic response and NAC para- 
meters were examined with the chi-square and Fisher’s 
exact tests. Progression-free survival (PFS) and overall sur-
vival (OS) were analyzed by the Kaplan-Meier method, and 
the difference of survival rates between metabolic respond-
ers and non-responders were compared by the log-rank test. 
Statistical analyses were conducted using IBM SPSS ver. 25.0 
for Windows (IBM Corp., Armonk, NY). All tests were two-
sided and p-values less than 0.05 were considered to indicate 
statistical significance.
7. Ethical statement
This study was approved by the Institutional Review 
Board of Severance Hospital at Yonsei University College 
of Medicine (No. 4-2018-0518), and the requirement of writ-
ten informed consent was waived due to the retrospective 
nature of the study.
Results
Eighty PET/CT scans were performed in 40 patients. The 
patients’ clinical, surgical, and pathological characteristics at 
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baseline are summarized in Table 1.
The baseline 18F-FDG-PET/CT was performed before ini-
tiation of NAC at a median interval of 4.5 days (range, 1 to 
17 days). The median time interval between the first cycle of 
NAC and the second (after the first cycle of NAC) 18F-FDG-
PET/CT was 19 days (range, 7 to 24 days). Median decrease 
in SUVmax between the baseline and after one cycle of NAC 
was 36.7% (range, –6.8% to 74.4%). One patient showed 
an increase in SUV after one cycle of NAC, and she was a 
metabolic non-responder. Of 39 patients who received IDS, 
we observed CRS 3 in 11 patients (27.5%) and no residual 
disease rate at IDS in 20 patients (50.0%). Median follow-up 
time was 19.7 months (range, 2.2 to 43.9 months). During this 
period, 18 patients experienced recurrence and eight of them 
died. Analysis of all 40 patients showed a median PFS of 21.0 
months (95% confidence interval [CI], 17.8 to 24.3), and the 
median OS was not reached.
 
Fig. 2.  Receiver operating characteristic analysis of ΔSUVmax 
(maximum standardized uptake value) for the identification of 
chemotherapy response score 3 after one cycle of neoadjuvant 
chemotherapy. AUC, area under the curve.
Fig. 3.  Scatter plots showing the decrease in maximum stand-
ardized uptake value (SUVmax) and cancer antigen 125 (CA-125) 
level before interval debulking surgery (IDS). Chemotherapy  
response score (CRS) 1 or 2 are indicated by blue circles, CRS 3 














































Table 1.  Patient characteristics 
Variable    Value (n=40)
Age at diagnosis (yr) 60.5 (39-77)
CA-125 level at diagnosis (U/mL) 1,846.5 (236.5-14,838.2)
CA-125 level before IDS (U/mL) 24.4 (6.4-1,222.8)
FIGO stage 
    IIIC 15 (37.5)
    IV 25 (62.5)
Histologic subtype 
    HGSC 40 (100)
Method of IDS 
    Laparotomy 7 (17.5)
    Laparotomy+HIPEC 22 (55.0)
    Laparoscopy 3 (7.5)
    Laparoscopy+HIPEC 7 (17.5)
    Not available 1 (2.5)
Residual disease after IDS 
    NGR 20 (50.0)
    ≤ 0.5 cm 17 (42.5)
    ≤ 1 cm 1 (2.5)
    ≤ 2 cm 1 (2.5)
    > 2 cm 1 (2.5)
    Not available 1 (2.5)
Fagotti score 
    8 13 (32.5)
    10 18 (45.0)
    12 5 (12.5)
    14 2 (5.0)
    Not available 2 (5.0)
Response rate before IDSa) 
    CR 3 (7.5)
    PR 37 (92.5)
    SD 0 (
    PD 0 (
CRS 
    1 1 (2.5)
    2 28 (70.0)
    3 11 (27.5)
NAC regimen 
    Paclitaxel+carboplatin 40 (100)
No. of NAC cycles 
    3 38 (95.0)
    4 2 (5.0)
Values are presented as median (range) or number (%). CA-
125, cancer antigen-125; IDS, interval debulking surgery; FIGO,  
Federation of Gynecology and Obstetrics; HGSC, high-grade  
serous carcinoma; HIPEC, hyperthermic intraperitoneal chemo- 
therapy; NGR, no gross residual disease; CR, complete response;  
PR, partial response; SD, stable disease; PD, progressive disease;  
CRS, chemotherapy response score; NAC, neoadjuvant chemo-
therapy. a)According to the Response Evaluation Criteria in Solid 
Tumors [22].
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1. The ΔSUVmax threshold value and CRS (CRS 1 or 2 vs. 
CRS 3–metabolic response) 
A cut-off of 40% of SUVmax decrease in metastatic sites 
offered the best accuracy in predicting CRS 3 (CR or near-
CR) with a sensitivity of 81.8%, specificity of 72.4%, and area 
under the curve of 0.72. The ROC curve is presented in Fig. 2. 
We selected the 40% cut-off to define the metabolic response; 
there were 17 (42.5%) metabolic responders (≥ 40% decrease 
in SUVmax) with a median decrease in SUVmax of 53.5% (range, 
40.7% to 74.4%) and 23 (57.5%) metabolic non-responders 
(< 40%) with a median decrease of 25.0% (range, –6.8% to 
39.7%). After one cycle of NAC, a threshold of 40% decrease 
in SUVmax was found to differentiate between pathologic 
non-responders (CRS 1 or 2) and responders (CRS 3) (Fig. 3). 
Fig. 4 shows that examples of metabolic responder and non-
responder observed in PET/CT and surgical findings before 
and after NAC.
2. Association between PET parameters and NAC param-
eters
There was a significant correlation between 18F-FDG-PET/ 
CT metabolic response and CRS. Metabolic responders had 
higher CRS 3 rate than metabolic non-responders (52.9% vs. 
8.7%, p=0.003). Furthermore, there was a close relationship 
between 18F-FDG-PET/CT metabolic response and CA-125 
normalization (< 35 U/mL) before IDS (76.5% vs. 39.1%, 
p=0.019). No residual tumor rate at IDS was 70.6% within 
metabolic responders and 31.8% within non-responders; 
and a significant correlation was observed between 18F-FDG- 
PET/ CT metabolic response and residual tumor at IDS (p= 
0.025). Only CR or PR were found as radiological response 
rate before IDS, and there was no significant correlation 
radiological response rate before IDS between metabolic 
responder and non-responder (p=0.069) (Table 2).
3. Metabolic response and survival
There was a significant association between metabolic 
response in 18F-FDG-PET/CT after one cycle of NAC and PFS 
(p=0.021), but not OS (p=0.335). Using defined 40% threshold 
for decrease in SUVmax from baseline after one cycle of NAC, 
median PFS was not reached in metabolic responders (n=17) 
compared with 18.5 months (95% CI, 13.9 to 23.0 months) in 
non-responders (n=23, p=0.021) (S1 Fig.). 
 
Fig. 4.  Examples of metabolic responder and non-responder. 18F-fluorodeoxyglucose positron emission tomography/computed tomog-
raphy images, at baseline and after one cycle of neoadjuvant chemotherapy (NAC) in metabolic responder (A) and non-responder (B). 
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Discussion
Our results demonstrated that tumor metabolic change 
after one cycle of NAC can be a valuable predictor of early 
response to chemotherapy, and potentially could identify 
metabolic responders and non-responders using a cut-off 
value of 40%.
In advanced-stage ovarian cancer, it is important to assess 
NAC response before IDS, as patients who do not respond 
to NAC seem to have less benefit from IDS. There is increas-
ing need for sensitive and specific non-invasive imaging 
methods for evaluating chemotherapy response for proper 
decision making in the management of ovarian cancer pati-
ents. 18F-FDG-PET/CT is a promising imaging method to 
evaluate NAC response and help to identify patients who 
response to treatment in ovarian cancer [10-13]. Avril et al. 
[10] showed that the sequential 18F-FDG-PET/CT after one 
cycle of NAC predicted patient outcome. Nishiyama et al. 
[11] evaluated the ability of 18F-FDG-PET/CT after five or six 
cycles of NAC to predict the response of NAC. Martoni et 
al. [12] reported the ability of 18F-FDG-PET/CT after three 
cycles of NAC to identify patients who would obtain benefits 
from prolonged NAC. Vallius et al. [13] evaluated the useful-
ness of 18F-FDG-PET/CT after three or four cycles of NAC for 
identifying patients who would not respond to NAC.
Furthermore, an early change of the treatment strategy 
could be considered to avoid delay of second-line chemothe-
rapy and risk of unnecessary postoperative complications. 
Therefore, it would also be valuable for detecting metabolic 
responders and non-responders at an early time-point. In 
consistent with results of Park et al. [9], we demonstrated 
that early tumor metabolic change after one cycle of NAC 
could predict chemotherapy response before IDS. To date, 
other than the results of these two studies, there are no data 
on the use of PET/CT after one cycle of NAC to assess treat-
ment response.
In this study, the optimal threshold of ΔSUVmax that dis-
criminate between metabolic responders and non-respond-
ers after one cycle of NAC was 40%. Considering the kine-
tics of tumor cell kill and the relationship to 18F-FDG-PET/ 
CT, we hypothesized that early metabolic change would 
differentiate chemotherapy response. As the number of 
NAC cycles increases, the number of cancer cells that can be 
detected by 18F-FDG-PET/CT decreases while the SUVmax 
value falls below the threshold that produced the difference 
in metabolic responder and non-responders; therefore, the 
metabolic difference between the two groups disappeared.
In 2009, Wahl et al. [23] proposed the PET response criteria 
in solid tumors (PERCIST) as a new standardized method 
by which the chemotherapy response was assessed by meta-
bolic changes. The SUL (lean body mass corrected SUV) is 
determined for up to five measurable target lesions, typically 
the five hottest lesions. A metabolic response is considered 
more than a 30% decrease in SUL peak between the pre- 
and posttreatment scans, although not necessarily the same 
lesion. Moreover, our study shows that the metabolic res-
ponse needed to be associated with a histopathologic res-
ponse to NAC should be more than the SUVmax changes of 
the PERCIST criteria.
Since multiple metastatic tumors and sites were present in 
advanced-stage ovarian cancer, it is difficult to evaluate the 
metabolic response in only one lesion. In this study, we eval-
Table 2.  Associations between PET parameters and outcome of NAC
Characteristic
                                                     40% of ΔSUVmax
 Responder (n=17) Non-responder (n=23) 
p-value
CA-125 level before IDS
    < 35 U/mL  13 (76.5) 9 (39.1) 0.019
    ≥ 35 U/mL 4 (23.5) 14 (60.9) 
Response rate before IDSa)   
    CR 3 (17.6) 0 ( 0.069
    PR 14 (82.4) 23 (100) 
Residual disease after IDS   
    NGR 12 (70.6) 7 (31.8) 0.025
    > 0 cm 5 (29.4) 15 (68.2) 
    Unknown 0 ( 1 ( 
CRS   
    1 or 2 8 (47.1) 21 (91.3) 0.003
    3 9 (52.9) 2 (8.7)
Values are presented as number (%). PET, positron emission tomography; NAC, neoadjuvant chemotherapy; SUVmax, maximum standard-
ized uptake value; CA-125, cancer antigen-125; IDS, interval debulking surgery; CR, complete response; PR, partial response; NGR, no 
gross residual disease; CRS, chemotherapy response score. a)According to the Response Evaluation Criteria in Solid Tumors [22].
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uated metabolic change regarding heterogeneous chemothe-
rapy response according to metastatic sites. 18F-FDG-PET/
CT parameters such as the SUVmax of the right and left up-
per quadrant, sub-hepatic area, mesentery, pelvis, as well as 
the right and left ovary were assessed in all patients. Chemo-
therapy response is expected to vary depending on the lo-
cation of primary and metastatic lesions due to intratumor 
heterogeneity in genomic profiles [24]. We mainly focused on 
the SUVmax values of the metastatic lesion with the lowest 
change in 18F-FDG uptake, as the metastatic tumor with the 
worst response would determine survival. 
There were several strengths in our study. First, we used 
CRS system to assess the pathologic response at IDS. We 
assessed the pathologic grading scale such as CRS system, 
which validated its prognostic significance, and high repro-
ducibility [18,19]. Second, our study was the homogenous 
study cohort consisting of advanced-stage ovarian cancer 
patients who received protocol-based treatment at our insti-
tution [21]. Third, a definite value for SUVmax change that 
discriminates between metabolic responders and non-res-
ponders was presented using the ROC curve analysis in this 
study.
One of the limitations in our study was its retrospective 
design. Another was the small number of patients, and the 
short follow-up period. It may be a factor in which metabolic 
response did not reflected in OS. Interpretation of this study 
must be confined to short-term results, and further inves-
tigation with a prospective design and large population is 
needed. 
In this study, using sequential 18F-FDG-PET/CT and his-
to-pathological response evaluation with CRS system, we 
identified patients who did not respond to NAC and were 
not likely to benefit from IDS. It is important to identify poor 
metabolic response patients to avoid the risk of unnecessary 
surgical complications and toxicity due to ineffective treat-
ment. In patients without metabolic response to NAC, the 
chemotherapy regimen may be changed to the second-line 
therapy or earlier oncologic surgery should be considered 
before the performance status gets worse. 18F-FDG-PET/CT 
could provide initial information on tumor response in pati-
ents without clinical or radiologic progression on whether to 
continue the same NAC regimen, change to a different regi-
men, or to discontinue the regimen.
In conclusion, the change in SUVmax after one cycle of NAC 
offers powerful stratification of patient outcomes, early, dur-
ing treatment. Therefore, 18F-FDG-PET/CT can be useful in 
identifying patients who will not respond to NAC and meta-
bolic non-responder might be candidates for second-line 
chemotherapy and clinical trials, instead of IDS.
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